secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-06-22T20:16:44+00:00
Accession:  0001517022-26-000043
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Akebia shareholders approve increase in authorized shares from 375M to 525M
---------------------------------------------------------------------------

- Authorized common stock increased from 350M to 500M shares; total authorized capital from 375M to 525M.
- Directors Adrian Adams, Michael Rogers, LeAnne Zumwalt elected as Class III for terms ending 2029.
- Non-binding say-on-pay approved with 89.8M for vs 51.1M against; frequency vote favored annual (112.9M votes).
- Ratification of Ernst & Young as auditor for FY2026 passed with 173.3M for vs 15.8M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/akba-20260617.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer